The Food and Drug Administration has placed sotorasib under priority review for patients with KRAS G12C-mutated locally advanced or metastatic NSCLC.
All articles by Rachel Narozniak, MA
The FDA has accepted a supplemental new drug application (sNDA) for brukinsa for the treatment of adults with Waldenström Macroglobulinemia (WM).
The Food and Drug Administration (FDA) has approved trilaciclib (Cosela; G1 Therapeutics, Inc.).
Latest News Your top articles for SundayFor More Personalized News
Haymarket Medical NetworkTop Picks
Continuing Medical Education (CME/CE) Courses